Nyrada gears up for Phase I clinical trials

Company News

by Finance News Network

Nyrada (ASX:NYR), a drug discovery company focused on small molecule therapies, has announced the successful completion of critical safety studies for its lead candidate NYR-BI03. The drug, designed to treat neuroprotective and cardioprotective conditions such as stroke and traumatic brain injury, is on track for its first-in-human clinical trials in late 2024.

Preclinical studies, including 14-day toxicology tests on rats and dogs, showed that NYR-BI03 was well tolerated, bolstering confidence in its safety profile. These findings will support Nyrada’s submission to the Human Ethics Research Committee, a key regulatory step for launching the Phase I trial. The upcoming study will assess the safety and pharmacokinetics of the drug in healthy volunteers, with results expected by mid-2025.

NYR-BI03 has demonstrated promising results in preclinical models, offering significant protection to brain tissue following a stroke and reducing heart damage by 86% in models of coronary ischaemia. This positions the drug as a potential game-changer in both neuroprotection and cardiovascular health.

Nyrada’s progress with NYR-BI03 marks a significant step forward in addressing unmet medical needs in both brain injury and heart disease, fields with considerable market potential.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?